Biotest - BT

BT - 062

BT-062 is a chimerized, toxin-coupled therapeutic monoclonal antibody, which, based on the current state of knowledge, binds to a target molecule on the cell surface of the multiple myeloma cells and thus destroys them.

Target indication (multiple myeloma)
Upside indications: other solid tumors

Scientific poster BT-062

The monoclonal antibody nBT062 conjugated to cytotoxic maytansinoids has potent and selective cytotoxicity against CD138 positive multiple myeloma cells in vitro and in vivo, 2008.

Phase I Study of BT062 Given As Repeated Single Dose Once Every 3 Weeks in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma, 2009

Multiple myeloma

Multiple myeloma is an aggressive cancer in certain blood cells which cannot currently be definitively cured.
more